Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-102 in Mild to Moderate Allergic Asthma
NCT01501942Phase 2Completed
- Sponsor
- AIM ImmunoTech
- Start
- Feb 2012
- Primary completion
- Feb 2013
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of interferon alfa-n3 in allergic asthma, sponsored by AIM ImmunoTech. Started Feb 2012; status: completed.
02
Drugs
interferon alfa-n3
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01501942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01501942.